Prezista (darunavir) has had its licence extended to include use in the treatment of HIV in antiretroviral-experienced children and adolescents over six years and weighing at least 20kg. Prezista should always be given in combination with low-dose ritonavir and other antiretrovirals.
Further information: Janssen-Cilag
In addition, Aptivus (tipranavir) is now licensed for the treatment of HIV in highly pre-treated adolescents 12 years of age or older with virus resistant to multiple protease inhibitors. The drug should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.
Further information: Boehringer Ingelheim